Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

por Cui, Xiaopei, Lu, Weida, Zhang, Deyuan, Qie, Liangyi, Li, Haijun, Li, Xiao, Liu, Hui, Ji, Qiushang
Publicado 2022

Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

por Li, Mengtao, Jing, Zhi-Cheng, Li, Yang, Huo, Yong, Yu, Zaixin, Zhang, Gangcheng, Zhu, Ping, Liu, Jinming, Ji, Qiushang, Wu, Bingxiang, Zhong, Jinhua, Wang, Pingping, Zhu, Wenjing, Zeng, Xiaofeng
Publicado 2020